HomeNew Drug ApprovalNew Drug Approval | USFDA Approves Vyvgart Hytrulo for Subcutaneous Use in...

New Drug Approval | USFDA Approves Vyvgart Hytrulo for Subcutaneous Use in Generalized Myasthenia Gravis


VYVGART® Hytrulo is the first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG)

SAN DIEGOJune 20, 2023 /PRNewswire/ — Halozyme Therapeutics, Inc. (NASDAQ: HALO) (“Halozyme”) today announced that argenx received U.S. Food and Drug Administration (FDA) approval for VYVGART® Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) injection with ENHANZE® for subcutaneous (SC) use for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

Halozyme Therapeutics, Inc. Logo. (PRNewsFoto/Halozyme Therapeutics, Inc.) (PRNewsfoto/Halozyme Therapeutics, Inc.)

VYVGART® Hytrulo is a subcutaneous product combination of efgartigimod alfa, a human IgG1 antibody fragment marketed for intravenous use as VYVGART®, and recombinant human hyaluronidase PH20 (rHuPH20), Halozyme’s ENHANZE® drug delivery technology to facilitate subcutaneous delivery of biologics. The product is to be administered subcutaneously by a healthcare professional as a single injection (1,008 mg fixed dose) over 30-90 seconds in cycles of once-weekly injections for four weeks.

“We are pleased that argenx has received FDA approval for the subcutaneous form of efgartigimod, which reinforces their commitment to the patient community with a broadening of treatment options that brings flexibility for patients,” said Dr. Helen Torley, president and chief executive officer of Halozyme. “We look forward to the multiple data readouts this year for subcutaneously administered efgartigimod in additional autoimmune conditions, with the potential to expand the number of approved indications and eligible patients.”

This FDA approval is based on positive results from the Phase 3 ADAPT-SC study, which established the efficacy of VYVGART® Hytrulo by demonstrating a reduction in anti-AChR antibody levels comparable to intravenous VYVGART® in adult gMG patients. ADAPT-SC was a bridging study to the Phase 3 ADAPT study, which formed the basis for approval of intravenous VYVGART® in December 2021.

Click to Download VYVGART USFDA Label


Tram Bui
VP, Investor Relations and Corporate Communications

Dawn Schottlandt
Argot Partners

SOURCE Halozyme Therapeutics, Inc.

Click Here to Read More on Halozyme


Please enter your comment!
Please enter your name here

- Advertisment -

Must Read

Medical Representative to Area Manager | What are Challenges | How...

Promotion from Medical Representative to Area Manager? Is it A GoalShift, A RoleShift, or A MindShift? Why Transition from Medical Representative to Area Manager...